Studies cardiovascular risk and treatment in people with type 2 diabetes in Italy
Records heart risk and diabetes medicine use in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy
Key facts
- Where
- Naples, ItalySee the site
Where in Italy
- Federico II University of Naples, Department of Advanced Biomedical SciencesNaples, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Federico II University
- Trial code
- NCT07375069
- Record updated
- 30 March 2026
- Original description
CardioMET is an observational, multicenter, real-life registry, intending to collect data on patients with Type 2 Diabetes Mellitus, attending internal medicine and cardiology outpatient clinics. The aim of the registry is to characterize the cardiovascular risk profile and pharmacological management of Type 2 Diabetes Mellitus in Italy, in accordance with current ESC and AHA guidelines for primary and secondary prevention of CV disease.Read full original descriptionShow less
Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy - CardioMET Registry
CardioMET is an observational, multicenter, real-life registry, intending to collect data on patients with Type 2 Diabetes Mellitus, attending internal medicine and cardiology outpatient clinics. The aim of the registry is to characterize the cardiovascular risk profile and pharmacological management of Type 2 Diabetes Mellitus in Italy, in accordance with current ESC and AHA guidelines for primary and secondary prevention of CV disease.
Inclusion: Age ≥ 18 years; Diagnosis of type 2 diabetes mellitus (T2DM); Stable clinical conditions; Outpatient settings; Ability to understand the study procedures and provide written informed consent.
Exclusion: Patients with type 1 diabetes mellitus; Any condition that may put the patient at risk by participating in the study; Active participation in interventional studies.